



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup>:C07D 487/04, A61K 31/40 // (C07D  
487/04, 209:00, 209:00)

A1

(11) International Publication Number:

WO 95/21171

(43) International Publication Date:

10 August 1995 (10.08.95)

(21) International Application Number: PCT/GB95/00203

(22) International Filing Date: 1 February 1995 (01.02.95)

(30) Priority Data:

9401994.0

2 February 1994 (02.02.94)

GB

(71) Applicants (for all designated States except US): THE  
WELLCOME FOUNDATION LIMITED [GB/GB]; Uni-  
corn House, 160 Euston Road, London NW1 2BP (GB).  
UNIVERSITY COLLEGE CARDIFF CONSULTANTS  
LIMITED [GB/GB]; Tower Building, Park Place, Cardiff  
CF1 3XR (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MILLER, David, Drysdale  
[GB/GB]; Langley Court, Beckenham, Kent BR3 3BS  
(GB). CHUNCHATPRASERT, Laddawan [TH/TH]; 244/6  
Yooyen Village, Mitraparp Road, Khon Kaen 4000 (TH).  
SHANNON, Patrick, Vivian, Richard [GB/GB]; Malverns,  
11 Clive Crescent, Penarth, South Glamorgan (GB).

(74) Agent: MCMUNN, W., P.; The Wellcome Foundation Limited,  
Langley Court, Beckenham, Kent BR3 3BS (GB).


(81) Designated States: AU, BR, CA, CN, CZ, FI, GE, HU, JP,  
KR, LT, MX, NO, NZ, PL, RU, SI, SK, UA, US, European  
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, ML, MR, NE, SN, TD, TG).

## Published


With international search report.

Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.


(54) Title: TRICYCLIC DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS




(I)




(a)



(b)



(c)



(d)

## (57) Abstract

A compound of formula (I) or a salt or physiologically functional derivative thereof, wherein A is (a), (b), (c), (d), X is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>, wherein R<sup>7</sup> is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl, sulphonyl, substituted sulphonyl, or COOMe; Y is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>; R<sup>1</sup> is COR<sup>8</sup>, CHO, CH<sub>2</sub>OH, CH<sub>2</sub>OR<sup>9</sup>, CONH<sub>2</sub>, COOR<sup>8</sup>, CONHR<sup>8</sup>, CONR<sup>8</sup>R<sup>9</sup>, CSOR<sup>8</sup>, CSSR<sup>8</sup>, COSR<sup>8</sup>, CSNHR<sup>8</sup>, CSNR<sup>8</sup>R<sup>9</sup>, CNHOR<sup>8</sup> wherein R<sup>8</sup> and R<sup>9</sup> are independently hydrogen, alkoxyalkyl, heterocycloalkyl, heteroaralkyl, or C<sub>1-10</sub> optionally substituted hydrocarbyl group which may optionally contain one or two oxygen atoms in the chain; or R<sup>8</sup> and R<sup>9</sup> are a sugar group. R<sup>2</sup> is H, halo, cyano, COOR<sup>8</sup>, alkyl, aryl, alkenyl, alkynyl, alkoxy, (wherein alkyl, aryl, alkenyl, alkynyl and alkoxy can be substituted) or CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R<sup>12</sup> wherein R<sup>12</sup> is alkyl or aryl; R<sup>3</sup> is H, alkyl, halogen, cyano, amino, COOR<sup>8</sup>, CONHR<sup>8</sup>, COR<sup>8</sup>, CH<sub>2</sub>OH, CH<sub>2</sub>OR<sup>8</sup>, CONH<sub>2</sub>, CONR<sup>8</sup>R<sup>9</sup>, CSOR<sup>8</sup>, CSSR<sup>8</sup>, COSR<sup>8</sup>, CSNHR<sup>8</sup>, CSNR<sup>8</sup>R<sup>9</sup> or CNHOR<sup>8</sup>; R<sup>4</sup> is H, halogen, cyano, amino, alkyl, COOR<sup>8</sup>, CONHR<sup>8</sup>, COR<sup>8</sup>, CH<sub>2</sub>OH, CH<sub>2</sub>OR<sup>8</sup>, CONH<sub>2</sub>, CONR<sup>8</sup>R<sup>9</sup>, CSOR<sup>8</sup>, CSSR<sup>8</sup>, COSR<sup>8</sup>, CSNHR<sup>8</sup>, CSNR<sup>8</sup>R<sup>9</sup> or CNHOR<sup>8</sup>; R<sup>5</sup> is H, hydroxy, aryloxy, aralkyloxy, alkyl, substituted alkyl, aralkyl, nitro, amino, halo, cyano COOR<sup>8</sup> or CHO; R<sup>6</sup> is H, aryl, alkyl, aralkyl, nitro, halogen, CHO or COR<sup>13</sup> wherein R<sup>13</sup> is alkyl or aryl; wherein R<sup>8</sup> is not H when R<sup>2</sup> is H and R<sup>3</sup> is not H or Me when A is (c). Processes for their preparation are described, together with their use in medicine, particularly cancer therapy and pharmaceutical formulations comprising the compounds.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## TRICYCLIC DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS

The present invention relates to heterocyclic compounds which have been found to have anti-tumour activity. More specifically, the invention concerns benzo[1,2-b:4,5-b']dipyrroles, benzo[1,2-b:5,4-b']dipyrroles, cyclopent[f]indoles, benzo[1,2-b:4,5-b']difurans, benzo[1,2-b:5,4-b']difurans, 2H-indeno[5,6-b]furans, benzo[1,2-b:4,5-b']dithiophenes, benzo[1,2-b:5,4-b']dithiophenes, cyclopent[f]indenes and 5H-furo[2,3-f]indoles methods for their preparation, pharmaceutical formulations containing them and their use as anti-tumour agents.

Research in the area of cancer chemotherapy has produced a variety of anti-tumour agents, which have differing degrees of efficacy. Standard clinically used agents include adriamycin, actinomycin D, methotrexate, 5-fluorouracil, cis-platinum, vincristine and vinblastine. However, these presently available anti-tumour agents are known to have various disadvantages, such as toxicity to healthy cells and resistance to certain tumour types.

There thus exists a continuing need to develop new and improved anti-tumour agents.


Khoshtariya et al, khim. Geterotsikl. Soedin (1982), (4) 304-7, disclose the synthesis of certain pyrroloindoles.

Gruenhaus H., J.Heterocyclic Chem. 13(6), 1161-3 discloses the synthesis of certain indenothiophenes


There have now been discovered novel compounds which exhibit anti-tumour cell activity including a group of

novel compounds which exhibit anti-tumour cell activity with low toxicity against normal cell lines.

Thus, in a first aspect the present invention provides a compound of the general formula (1)



or a salt or physiologically functional derivative thereof,  
wherein A is



X is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>, wherein R<sup>7</sup> is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl, sulphonyl, substituted sulphonyl, or COOMe;

Y is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>;

R<sup>1</sup> is COR<sup>8</sup>, CHO, CH<sub>2</sub>OH, CH<sub>2</sub>OR<sup>8</sup>, CONH<sub>2</sub>, COOR<sup>8</sup>, CONHR<sup>8</sup>, CONR<sup>8</sup>R<sup>9</sup>, CSOR<sup>8</sup>, CSSR<sup>8</sup>, COSR<sup>8</sup>, CSNHR<sup>8</sup>, CSNR<sup>8</sup>R<sup>9</sup>, CNHOR<sup>8</sup> wherein R<sup>8</sup> and

$R^9$  are independently hydrogen, alkoxyalkyl, heterocycloalkyl, heteroaralkyl, or  $C_{1-10}$  optionally substituted hydrocarbyl group which may optionally contain one or two oxygen atoms in the chain;

or  $R^9$  and  $R^9$  are a sugar group.


$R^2$  is H, halo, cyano,  $COOR^8$ , alkyl, aryl, alkenyl, alkynyl, alkoxy, (wherein alkyl, aryl, alkenyl, alkynyl and alkoxy can be substituted) or  $CH_2CH_2CO_2R^{12}$  wherein  $R^{12}$  is alkyl or aryl;

$R^3$  is H, alkyl, halogen, cyano, amino,  $COOR^8$ ,  $CONHR^8$ ,  $COR^8$ ,  $CH_2OH$ ,  $CH_2OR^8$ ,  $CONH_2$ ,  $CONR^8R^9$ ,  $CSOR^8$ ,  $CSSR^8$ ,  $COSR^8$ ,  $CSNHR^8$ ,  $CSNR^8R^9$  or  $CNHOR^8$ ;

$R^4$  is H, halogen, cyano, amino, alkyl,  $COOR^8$ ,  $CONHR^8$ ,  $COR^8$ ,  $CH_2OH$ ,  $CH_2OR^8$ ,  $CONH_2$ ,  $CONR^8R^9$ ,  $CSOR^8$ ,  $CSSR^8$ ,  $COSR^8$ ,  $CSNHR^8$ ,  $CSNR^8R^9$  or  $CNHOR^8$ ;

$R^5$  is H, hydroxy, aryloxy, aralkyloxy, alkyl, substituted alkyl, aralkyl, nitro, amino, halo, cyano  $COOR^8$  or CHO;

$R^6$  is H, aryl, alkyl, aralkyl, nitro, halogen, CHO or  $COR^{13}$  wherein  $R^{13}$  is alkyl or aryl; wherein  $R^8$  is not H when  $R^2$  is H and  $R^3$  is not H or Me when A is



Alkyl groups present in general formula (I) may be

straight or branched chain alkyl groups, and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, t-butyl and the like.

Acyl groups may be straight or branched and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of suitable acyl groups include ethanoyl and propanoyl groups.

Alkoxy may be straight or branched and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of suitable alkoxy groups include methoxy, ethoxy and the like.

Aryl includes both carbocyclic aryl groups and heterocyclic aryl groups normally containing a maximum of 10 ring atoms. Carbocyclic aryl groups include, eg phenyl and naphthyl and contain at least one aromatic ring. Heterocyclic aryl groups include eg thienyl, furyl, pyridyl, indole and quinoline rings.

An aralkyl group may contain from 1 to 4 atoms in the alkyl portion and the aryl portion may be a carbocyclic or heterocyclic aryl group.

Cycloalkyl includes both cycloalkyl groups and heterocyclo alkyl groups normally containing between 3 and 6 ring atoms. Heterocycloalkyl groups include e.g. morpholino, thiomorpholino, piperidino, imidazolino, pyrrolidino, pyrazolidino, piperazino, tetrahydrofuranyl, tetrahydropyranyl.

When R<sup>o</sup> and R<sup>o</sup> are independently optionally substituted

C<sub>1-10</sub> hydrocarbyl which may optionally contain one or two oxygen atoms in the chain this includes optionally substituted alkyl, hydroxyalkyl, alkenyl, alkynyl, carbamoylalkyl, alkoxyalkyl, cycloalkyl, cycloalkenyl, aralkyl, aryloxyalkyl.

Substituents which may be present on the C<sub>1-10</sub> hydrocarbyl group which may optionally contain one or two oxygen atoms in the chain include hydroxy, azido, alkenyl, halo, nitro (NO<sub>2</sub>), amino, (optionally substituted by one or 2 alkyl groups), cyano, carboxylate, alkyl ester, aralkyl esters or aryl esters, (wherein the alkyl ester, aralkyl ester and aryl ester can be substituted) alkyl, aryl, aralkyl, aryloxy, arylalkoxy, substituted arylalkoxy, sulphinyl, sulphonyl, thio, alkylthio, alkoxy, hydroxyalkyl, halo alkyl, phosphate, phosphonate, silyl, silyloxy, (wherein silyl and silyloxy may be substituted by one or more C<sub>1-6</sub> alkyl or aryl) keto, formyl. Substituents which may be present on alkyl esters, aralkyl esters and aryl esters include nitro, amino, hydroxy, alkoxy, halogen, cyano and alkyl.

Where R<sup>\*</sup> is a sugar this group may be present in a protected or unprotected form. Preferred sugar-protecting groups include isopropylidene, benzylidene acetate, benzoyl, paranitrobenzyl, paranitrobenzoyl, benzyl, substituted silyl and tetrahydropyranyl.


When R<sup>\*</sup> is a sugar such as a tetrose, pentose, hexose (including furanose and pyranose) or heptose, preferred sugars include glucose, fructose, mannose, ribose, arabinose.

Substituents which may be present on the sulphonyl and

sulphinyl include alkyl, aryl and aralkyl.

Halogen represents fluoro, chloro, bromo or iodo.

X preferably represents NH, A is preferably



and Y preferably represents NH.

R<sup>1</sup> is preferably COOR<sup>s</sup>, with R<sup>s</sup> preferably being alkyl or aralkyl.

R<sup>2</sup> is preferably H, alkyl, or COOR<sup>s</sup> wherein R<sup>s</sup> is preferably alkyl,

R<sup>3</sup> is preferably alkyl

R<sup>4</sup> is preferably alkyl or COOR<sup>s</sup>.

R<sup>5</sup> is preferably hydrogen and

R<sup>6</sup> is preferably hydrogen or methyl

and salts and physiologically functional derivatives thereof.

One group of preferred compounds according to the present invention includes:

Ethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2-carboxylate;

Diethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2,5-dicarboxylate; and

Ethyl 6-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate

and physiologically functional derivatives thereof.

A second group of preferred compounds according to the invention include:

Ethyl 6-Benzyloxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate;

Dibenzyl 3,4-dimethylpyrrolo[3,2-f]indole-2,6-dicarboxylate;

Ethyl 7-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate; and


Ethyl 3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate

and physiologically functional derivatives thereof.


Compounds of the general formula (I) have been tested against two specially developed cell lines which are clones of the human fibrosarcoma cell-line, HT1080. One clone, HT1080scc2, retains the transformed phenotype of the parental line, whilst the other, HT10801c, is a morphologically flat, non-tumourigenic, revertant.

According to a further aspect, the present invention also provides a process for preparing compounds of general formula (I), which process comprises the catalysed reaction of a compound of formula (II) with a compound of formula (III) in an inert solvent at a temperature

between room temperature and the reflux temperature of the solvent, wherein X, Y, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined herein except that R<sup>3</sup> and R<sup>4</sup> may not be hydrogen when X is NH, and L is a leaving group:-



(II)



(III)

Preferred catalysts are Montmorillonite K<sub>10</sub> clay or p-toluenesulphonic acid. Preferred solvents are 1,2-dichloroethane or toluene. Examples of suitable leaving groups include -OCOCH<sub>3</sub>, OEt, -N<sup>+</sup>Me, and halo.

Insertion of the substituent R<sup>1</sup> onto the ring system for example:

- (d) Carboxylation of a polyheterocyclic compound using
  - (i) a carbonyl halide or
  - (ii) carbon dioxide

According to known procedures (J. March, Advanced Organic Chemistry, 2nd ed, McGraw Hill, New York, 1977, p 497-498).

- (e) Alternatively one can produce compounds of the formula (I) wherein R<sup>2</sup> is CHO by methods known to those

skilled in the art, for example:-

- (i) The appropriate aromatic polyheterocycle can be reacted with a formylating agent, such as that generated by the reaction between  $\text{SnCl}_4$  and  $\text{Cl}_2\text{CHOCH}_3$  or equivalent reagents.

For example, according to the method of A. Reiche et al, Chem. Ber. 93, 88 (1960), or with other standard formylating reagents/procedures known in the art, for example, the Gatterman-Koch reaction ( $\text{CO}\backslash\text{HCl}\backslash\text{AlCl}_3\backslash\text{CuCl}$ ), the Gatterman reaction ( $\text{HCN}\backslash\text{HCl}\backslash\text{ZnCl}_2$ ), and the Vilsmeier reaction ( $\text{POCl}_3\backslash\text{PhN}-(\text{Me})\text{CHO}$  or  $\text{POCl}_3\backslash\text{Me}_2\text{CHO}$ ) (J. March, Vide Supra, p 494-497); or

- (ii) the appropriate aromatic polyheterocycle, carrying a suitable functional group, said group being converted to an aldehyde group by methods known to those skilled in the art. Suitable functional groups include  $\text{CHBr}_2$ ,  $\text{CH}_3$ ,  $\text{COR}^{14}$  wherein  $\text{R}^{14}$  is a primary or secondary  $\text{C}_{1-6}$  alkyl group,  $\text{COOH}$  or a derivative thereof such as an ester, amide, acid chloride or  $\text{CN}$ ; or

(f) Compounds of the formula (I) wherein  $\text{R}^1$  is  $\text{CONHR}^{10}$  may also be produced by the reaction of a compound wherein  $\text{R}^1$  is  $\text{COOH}$  or a suitable reactive acid derivative thereof as outlined in J. March, Vide supra. For example an acid halide can be reacted with a compound  $\text{NH}_2\text{R}^{10}$  in an inert solvent.

(g) Conversion of one compound of formula (I) into another compound of formula (I).


Compounds of the invention wherein  $R^1$  is  $\text{COOR}^8$  and  $R^8$  is, for example, aralkyl can be converted to free acids wherein  $R^8$  is H by reduction in the presence of  $\text{H}_2$  and a Pd catalyst, or where  $R^8$  is, for example, alkyl, by hydrolysis in the presence of an appropriate base e.g. caesium carbonate.

It is thereafter possible for the skilled man to synthesise ester and amide compounds within the scope of the invention by conversion of the free acids obtained, by known procedures. (See J. March, Vide Supra, p363-365).

Compounds of the invention produced as described herein can be converted to other compounds of the invention by electrophilic substitution at  $R^5$  and/or  $R^6$ , to introduce, for example,  $\text{NO}_2$ , halogen and  $\text{COR}^{13}$  wherein  $R^{13}$  is as defined herein.


Compounds of formula I in which X or Y is  $\text{NR}_7$  and  $R_7$  is  $\text{COOMe}$  can be converted by acid or base hydrolysis to compounds of formula I in which X or Y are NH using, for example, potassium hydroxide or HBr in acetic acid.

The above processes have been described for compounds wherein A is



The skilled man will appreciate that these are equally

applicable when A is



The compounds of the present invention are useful for the treatment of tumours. They may be employed in treating various forms of cancer of mammals including carcinomas, for instance of the stomach, pancreas, breast, uterus and colon; adenocarcinomas, for instance of the lung and colon; sarcomas, for instance fibrosarcoma; leukaemias, for instance lymphocytic leukaemia and lymphomas, for instance myeloid lymphoma.

The invention thus further provides a method for the treatment of tumours in animals, including mammals, especially humans, which comprises the administration of a clinically useful amount of compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative in a pharmaceutically useful form, once or several times a day or in any other appropriate schedule, orally, rectally, parenterally, or applied topically.

In addition, there is provided as a further, or alternative, aspect of the invention, a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof for use in therapy, for example as an antitumour agent.

The amount of compound of formula (I) required to be effective against the aforementioned tumours will, of

course, vary and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, and nature of the formulation, the mammal's body weight, surface area, age and general condition, and the particular compound to be administered. A suitable effective anti-tumour dose is in the range of about 0.01 to about 100 mg/kg body weight, eg 0.1 to about 100 mg/kg body weight, preferably 1-30 mg/kg body weight. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day or by intravenous infusion for selected duration. For example, for a 75 kg mammal, the dose range would be about 8 to 900 mg per day, and a typical dose could be about 50 mg per day. If discrete multiple doses are indicated treatment might typically be 15 mg of a compound of formula (I) given up to 4 times per day.

Whilst it is possible for the active compound to be administered alone, it is preferable to present the active compound in a pharmaceutical formulation. Formulations of the present invention, for medical use, comprise a compound of formula (I) or a salt thereof together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The carrier(s) should be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The present invention, therefore, further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof together

with a pharmaceutically acceptable carrier thereof.

There is also provided a method for the preparation of a pharmaceutical formulation comprising bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier thereof.

Formulations according to the present invention include those suitable for oral, topical, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred formulations are those suitable for oral or parenteral administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product into desired formulations.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a solution or suspension in an aqueous or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active compound with any suitable carrier.

A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredients. Such accessory ingredients(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredients, such as a polyhydric alcohol for example glycerol or sorbitol.

Formulations for rectal administration may be presented as a suppository with a conventional carrier such as cocoa butter.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution of a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that is isotonic with the blood of the recipient.

Useful formulations also comprise concentrated solutions or solids containing the compound of formula (I) which

upon dilution with an appropriate solvent give a solution for parenteral administration as above.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

In a further aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours.

The invention will now be illustrated by the following non-limiting Examples:

All temperatures are in degrees Celsius (°C)

IR spectra were recorded on a Perkin-Elmer 257 grating spectrophotometer or a Bruker FS66 spectrophotometer.

U.V. spectra were measured in ethanol on a Unicam SP800 spectrophotometer.

<sup>1</sup>H NMR spectra were obtained on a Bruker WM 360-NMR spectrophotometer at 360 MHz, or on a Bruker AC200 spectrophotometer at 200 MHz. J values are given in Hz.

Mass spectra were obtained on Varian CH5D(EI), Kratos Concept (EI) or Kratos Ms50(FAB) instruments.

EXAMPLE 1**Diethyl 1,5-dihydro-3,4,6-trimethylpyrrolo[2,3-f]indole-2,7-dicarboxylate**

A solution of ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate (0.267 g, 1.0 mmol) and 3-carbethoxy-2-methylpyrrole (0.153 g, 1.0 mmol) in 1,2-dichloroethane (10 cm<sup>3</sup>) was heated at reflux and stirred with Montmorillonite clay (1g) for 18h. After filtration from clay and washing well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. This oil was submitted to flash chromatography on silica eluting with (0-20%) ethyl acetate in dichloromethane to give the starting 3-carbethoxy-2-methylpyrrole (0.045 g, 29.4%) and diethyl 1,5-dihydro-3,4,6-trimethylpyrrolo[2,3-f]indole-2,7-dicarboxylate as a colourless solid (0.021g, 6.14%) m.p. 269°C (decomp);  $\delta$ H ([<sup>2</sup>H<sub>6</sub>]-DMSO) 11.34 (1H, s, 5-NH), 11.00 (1H, s, 1-NH), 7.80 (1H, s, 8-H), 4.33 (2H, q, 7-OCH<sub>2</sub>CH<sub>3</sub>), 4.26 (2H, q, 2-OCH<sub>2</sub>CH<sub>3</sub>), 2.85 (6H, s, 3-CH<sub>3</sub> and 4-CH<sub>3</sub>), 2.69 (3H, s, 6-CH<sub>3</sub>), 1.39 (3H, t, 7-OCH<sub>2</sub>CH<sub>3</sub>), and 1.37 (3H, t, 2-OCH<sub>2</sub>CH<sub>3</sub>); saturation of the singlet 8-H at  $\delta$  7.80 enhanced the signal due to 1-NH at  $\delta$  11.00 (2.3%); m/z (%) 342 (75, M<sup>+</sup>), 296 (100), 268 (6), 223 (7) and 195 (5) (Found : M<sup>+</sup> 342.1580. C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires M, 342.1579;  $\lambda$  max EtOH/nm (log  $\epsilon$  max.dm<sup>3</sup> mol<sup>-1</sup> cm<sup>-1</sup> 378 (3.56), 365 sh (353), 329 (3.83), 3.04 (3.99) and 259 (3.74). Further elution gave diethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2,5-dicarboxylate as a colourless solid (0.048g, 14%) m.p. 216-216.5°C (Found: C, 66.82; H, 6.68; N, 8.17. C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires C, 66.65; H, 6.48, N, 8.18%);  $\delta$  ([<sup>2</sup>H<sub>6</sub>]-

DMSO) 11.30 (1H, s, 7-NH), 10.91 (1H, s, 1N-H), 7.12 (1H, s, 8-H), 4.35 (2H, q, 5-OCH<sub>2</sub>CH<sub>3</sub>), 4.28 (2H, q, 2-OCH<sub>2</sub>CH<sub>3</sub>), 2.90 (3H, s, 4-CH<sub>3</sub>), 2.87 (3H, s, 3-CH<sub>3</sub>), 2.54 (3H, s, 6-CH<sub>3</sub>), 1.36 (3H, t, 5-OCH<sub>2</sub>CH<sub>3</sub>) and 1.34 (3H, t, 2-OCH<sub>2</sub>CH<sub>3</sub>); saturation of the 8-H proton at  $\delta$  7.12 enhanced the signals due to 7-NH at  $\delta$  11.30 (2.4%) and 1-NH at  $\delta$  10.91 (1.8%); m/z (%) 342 (64, M<sup>+</sup>), 296 (100), 250(5), and 194(9);  $\lambda$  max (EtOH)/nm (log  $\epsilon$  max/dm<sup>3</sup> mol<sup>-1</sup> cm<sup>-1</sup>) 340 (4.10), 327.5 (4.53) and 270 (4.46), and the starting 5-acetoxymethyl-4-acetylpyrrole (0.029 g, 10.9%).

## EXAMPLE 2

### **Ethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2-carboxylate**

The general procedure of Example 1 was followed using ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrolo-2-carboxylate (0.692g, 2.59mmol), 3-methoxycarbonyl-2-methylpyrrole (0.360g, 2.59mmol), 1,2-dichloroethane (25 cm<sup>3</sup>) and Montmorillonite clay (2g). Chromatographic separation using (0-20%) ethyl acetate in dichloromethane gave ethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2-carboxylate as a pale yellow solid (0.0124g, 1.8%) m.p. 213-216°C (decomp);  $\delta$ H ([<sup>2</sup>H<sub>6</sub>]-DMSO) 10.70 (1H, s, 1-NH), 10.41 (1H, s, 7-NH), 7.03 (1H, s, 8-H), 6.14 (1H, s, 5-H), 4.33 (2H, q, CH<sub>2</sub>CH<sub>3</sub>), 2.85 (3H, s, 3-CH<sub>3</sub>), 2.78 (3H, s, 4-CH<sub>3</sub>), 2.37 (3H, s, 6-CH<sub>3</sub>), and 1.35 (3H, s, OCH<sub>2</sub>CH<sub>3</sub>); saturation of the 8-H proton at  $\delta$  7.03 enhanced the signals due to 1-NH at  $\delta$  10.70 (3.5%) and 7-NH at  $\delta$  10.41 (2.9%) and saturation of the 5-H proton at  $\delta$  6.14 enhanced the signals due to 4-CH<sub>3</sub> at 2.78 (2%) and 6-CH<sub>3</sub> at 2.37 (0.6%); m/z (%) 270 (M<sup>+</sup>, 49), 234 (100), 196 (17)

(Found:  $M^+$  270.1337.  $C_{16}H_{18}N_2O_2$  requires  $M$  270.368, and the starting 3-methoxycarbonyl-2-methylpyrrole (0.108 g, 30%). Further elution gave ethyl methyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2,5-dicarboxylate as a colourless solid (0.066 g, 7.8%) m.p. 247-250 °C (Found: C, 66.11; H, 6.37; N, 8.47.  $C_{18}H_{20}N_2O_4$  requires C, 65.84; H, 6.14; N, 8.53);  $\delta H$  ( $[^2H_6]$ -DMSO) 11.33 (1H, s, 7-NH), 10.91 (1H, s, 1-NH), 7.21 (1H, s, 8-H), 4.35 (2H, q,  $OCH_2CH_3$ ), 3.78 (3H, s,  $OCH_3$ ), 2.88 (3H, s,  $CH_3$ ), 2.87 (3H, s,  $CH_3$ ), 2.53 (concealed by DMSO, 6- $CH_3$ ) and 1.37 (3H, t,  $OCH_2CH_3$ ); m/z (%) 328 (64,  $M^+$ ), 297 (5), 282 (100), 250 (6), 221 (6) and 194 (17) and the starting 5-acetoxymethyl-4-acetylpyrrole (0.037 g, 5.4%).

### EXAMPLE 3

Ethyl 6-Benzylloxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate;

(a) Reaction of benzyl pyrrole-2-carboxylate and ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate

A solution of benzyl pyrrole-2-carboxylate (0.615 g, 3.06 mmol) and ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate (0.809, 3.01 mmol) in 1,2-dichloroethane (30 cm<sup>3</sup>) was heated under reflux and stirred with Montmorillonite clay (3 g) for 7 h. The reaction was followed to completion by TLC. After the clay had been filtered off and washed well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave a yellow oil. This was submitted to column

chromotagrophy eluting with (5-50%) ethyl acetate in n-hexane to give the starting pyrrole, benzylpyrrole-2-carboxylate (0.153 g, 24.80%) Ethyl 6-Benzylloxycarbonyl-3,4-dimethylpyrrolo[2,3-f]indole-2-carboxylate (isomer I) as a yellow solid (0.043 g, 3.67%), m.p. 218-220°C (Found: C, 70.90; H, 5.87; N, 7.34.  $C_{23}H_{22}N_2O_4$  requires C, 70.75; H, 5.68; N, 7.18%);  $\delta H$  ( $[^2H_6]$ -DMSO) 11.18 (1H, br s, 5-NH), 10.97 (1H, br s, 1-NH), 7.52 (2H, d J 7, Q-H's of ArH), 7.36-7.48 (3H, m, m and p H's of ArH), 7.46 (1H, s, 8-H), 7.23 (1H, d J 1.5, 7-H), 5.41 (2H, s, OCH<sub>2</sub>Ph), 4.35 (2H, q, OCH<sub>2</sub>CH<sub>3</sub>), 2.93 (3H, s, 4-CH<sub>3</sub>), 2.85 (3H, s, 3-CH<sub>3</sub>) and 1.38 (3H, t, OCH<sub>2</sub>, CH<sub>3</sub>); m/z (%) 390 (100, M<sup>+</sup>), 344 (71), 282 (59), 236 (60), 228 (27), 209 (21) and 91 (78); V max (nujol) 3400, 3350, 1725 and 1680 cm<sup>-1</sup>; and Ethyl 6-Benzylloxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate (isomer II) as a yellow solid (0.065 g, 5.55%), m.p. 179-182°C,  $\delta H$  ( $[^2H_6]$ -DMSO) 11.36 (1H, br s, 7-NH), 10.95 (1H, br s, 1-NH), 7.52 (2H, d J 7, Q-H's of ArH), 7.48-7.37 (3H, m, m and p H's of ArH), 7.34 (1H, br s, 5-H), 7.19 (1H, br s, 8-H), 5.39 (2H, s, CH<sub>2</sub>Ph), 4.35 (2H, q, OCH<sub>2</sub>CH<sub>3</sub>), 2.89 (3H, s, 4-CH<sub>3</sub>), 2.84 (3H, s, 3-CH<sub>3</sub>) and 1.37 (OCH<sub>2</sub>, CH<sub>3</sub>); m/z (%) 390 (4, M<sup>+</sup>), 344 (7), 306 (5), 282 (5), 236 (6), 209 (15), 154 (18), 127 (19) and 91 (100) (Found: M<sup>+</sup> 390.1580.  $C_{23}H_{22}N_2O_4$  requires 390.1579).

Also obtained were 2-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)-5-benzoxycarbonylpyrrole as off white crystals after crystallisation from dichloromethane-petroleum ether (0.303 g, 24.75%), m.p. 130-132°C,  $\delta H$  ( $[^2H_6]$ -DMSO) 11.96 (1H, s, 1-NH), 11.65 (1H, s, 1'-NH), 7.45-2.31 (5H, m, ArH), 6.70 (1H, t J2.6, 4-H), 5.75 (1H, dd J 2.6 and 4, 3-H), 5.27 (2H, s, CH<sub>2</sub>Ph), 4.28 (2H, q, OCH<sub>2</sub>CH<sub>3</sub>), 4.20 (2H, s, CH<sub>2</sub>), 2.50 (concealed

by DMSO, 4'-CH<sub>3</sub>), 2.34 (3H, s, COCH<sub>3</sub>) and 1.31 (3H, t, OCH<sub>2</sub>CH<sub>3</sub>); saturation of the 4-H at  $\delta$  6.70 enhanced the signal due to 3-H double doublet at  $\delta$  5.75 (6%) and saturation of the singlet CH<sub>2</sub> at  $\delta$  4.20 enhanced the signals due to 3-H at  $\delta$  5.75 (4.5%), 1-NH at  $\delta$  11.96 (4.5%) and 1'-NH at  $\delta$  11.65 (4.5%); m/z (%) 408 (14, M<sup>+</sup>), 317 (100), 271 (97), 91 (47) (Found: M<sup>+</sup>NH<sub>4</sub><sup>+</sup> 426.2029. C<sub>23</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>+NH<sub>4</sub><sup>+</sup> requires 426.2028) and 2,3-di(3'-acetyl-5'-ethoxycarbonyl-4'-methyl-2'-ylmethyl)-5-benzoxycarbonylpyrrole as colourless crystals after crystallisation from benzene-petroleum ether (0.256 g, 27.75%), m.p. 164-166°C (Found: C, 66.53; H, 6.24; N, 6.71. C<sub>34</sub>H<sub>37</sub>N<sub>3</sub>O<sub>8</sub> requires C, 66.33; H, 6.06; N, 6.83%);  $\delta$ H (CDCl<sub>3</sub>), 10.50 (1H, br s, 1-NH), 9.10 (2H, br s, 2X NH), 7.42-7.20 (5H, m, ArH), 6.65 (1H, d J 2.5, 4-H), 5.23 (2H, s, CH<sub>2</sub>Ph), 4.32 (2H, q, 2-OCH<sub>2</sub>CH<sub>3</sub>), 4.30 (2H, q, 3-OCH<sub>2</sub>CH<sub>3</sub>), 4.13 (2H, s, 2-CH<sub>2</sub>), 4.08 (2H, s, 3-CH<sub>2</sub>), 2.60 (3H, s, CH<sub>3</sub>), 2.59 (3H, s, CH<sub>3</sub>), 2.55 (3H, s, COCH<sub>3</sub>), 2.54 (3H, s, COCH<sub>3</sub>), 1.36 (3H, t, 2-OCH<sub>2</sub>CH<sub>3</sub>) and 1.35 (3H, t, 3-OCH<sub>2</sub>CH<sub>3</sub>).

(b) Cyclisation of 2-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl-5-benzoxycarbonylpyrrole

A solution of the 2-pyrrolylmethylpyrrole (0.083 g), 0.2 mmol) in 1,2-dichloroethane (5 ml) was heated under reflux and stirred with Montmorillonite clay (0.25 g) for 14 h. The reaction was followed by TLC. After the clay has been filtered off and washed well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. Chromatographic separation of an oil eluting with (5-30%) ethyl acetate in hexane yielded Ethyl 6-Benzoyloxycarbonyl-3,4-dimethylpyrrolo[2,3-f]indole-2-carboxylate

(isomer I) as a yellow solid (0.0047 g, 6%) which was identical to isomer I obtained from (a) by TLC and nmr; and Ethyl 6-Benzylloxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate (isomer II) as a yellow solid (0.0285 g, 36%) which was identical to isomer II obtained from (a) by TLC and NMR; and the starting 2-pyrrolylmethylpyrrole (0.0116 g, 14%).

#### EXAMPLE 4

#### **Dibenzyl 3,4-dimethylpyrrolo[3,2-f]indole-2,6-dicarboxylate**

A solution of benzyl pyrrole-2-carboxylate (0.201 g, 1.0 mmol) and benzyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate (0.331 g, 1.0 mmol) in 1,2-dichloroethane (10 cm<sup>3</sup>) was heated under reflux and stirred with Montmorillonite clay (1 g) for 7 h. The reaction was followed to completion by TLC. After the clay had been filtered off and washed well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. This was submitted to column chromatography eluting with (5-50%) ethyl acetate in hexane to give Dibenzyl 3,4-dimethylpyrrolo[2,3-f]indole-2,6-dicarboxylate (isomer I) as yellow crystals after crystallisation from ethyl acetate-petroleum ether (0.019 g, 4.20%), m.p. 210-212°C (Found: C, 73.50; H, 5.29; N, 6.13. C<sub>28</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub> requires C, 73.62; H, 5.49; N, 6.36%);  $\delta$ H ([<sup>2</sup>H<sub>6</sub>]-DMSO) 11.17 (1H, s, 5-NH), 11.02 (1H, s, 1-NH), 7.57-7.34 (11H, m, 2 x ArH and 8-H), 7.23 (1H, d J 1.5, 7-H), 5.42 (2H, s, CH<sub>2</sub>Ph), 5.40 (2H, s, CH<sub>2</sub>Ph), 2.93 (3H, s, 4-CH<sub>3</sub>), 2.87 (3H, s, 3-CH<sub>3</sub>); m/z (%) 452 (68, M<sup>+</sup>), 344 (58), 236 (17), and 91 (100); and Dibenzyl 3,4-dimethylpyrrolo[3,2-f]indole-2,6-

dicarboxylate (isomer II) as yellow crystals after crystallisation from dichloromethane-petroleum ether (0.036 g, 7.96%), m.p. 184-186°C (Found: C, 73.71; H, 5.59; N, 6.27.  $C_{28}H_{24}N_2O_4$  requires C, 73.62; H, 5.49; N, 6.36%);  $\delta H$  ( $[^2H_6]$ -DMSO) 11.36 (1H, s, 7-NH), 10.99 (1H, s, 1-NH), 7.52 (4H, d J 7, O-ArH), 7.46-7.37 (7H, m, m and p-ArH and 8-H), 7.23 (1H, br s, 5-H), 5.40 (4H, s, 2x CH<sub>2</sub>Ph), 2.91 (3H, s, 3-CH<sub>3</sub>) and 2.86 (3H, s, 4-CH<sub>3</sub>); m/z (%) 452 (55,  $M^+$ ), 344 (59), 236 (10), and 91 (100). Further elution gave 2-(3'-acetyl-5'-benzoxycarbonyl-4-methylpyrrol-2'-ylmethyl)-5-benzoxycarbonylpyrrole as pale yellow crystals after crystallisation from dichloromethane-petroleum ether (0.104 g, 22.13%), m.p. 141-143°C (Found: C, 71.60; H, 5.59; N, 5.79.  $C_{28}H_{26}N_2O_5$  requires C, 71.47; H, 5.57; N, 5.95%);  $\delta H$  ( $CDCl_3$ ) 10.22 (1H, s, 1-NH), 9.25 (1H, s, 1'-NH), 7.48-7.28 (10H, m, ArH), 6.83 (1H, dd J 2.5 and 4, 4-H), 6.05 (1H, dd J 2.5 and 4, 3-H), 5.28 (2H, s, CH<sub>2</sub>Ph), 5.26 (2H, s, CH<sub>2</sub>Ph), 4.13 (2H, s, CH<sub>2</sub>), 2.58 (3H, s, CH<sub>3</sub>), 2.49 (3H, s, COCH<sub>3</sub>); m/z (%) 470 (6,  $M^+$ ), 379 (45), 271 (32), 91 (100), 65 (61) and 43 (38) and 2,3-di(3'-acetyl-5'-benzoxycarbonyl-4'-methylpyrrole-2'-ylmethyl)-5-benzoxycarbonylpyrrole as an oil (0.0924 g, 25.01%);  $\delta H$  ( $CDCl_3$ ) 11.18 (1H, s, 1-NH), 10.46 (1H, s, NH), 9.31 (1H, s, NH), 7.42-7.27 (15H, m ArH), 6.61 (1H, d J 2, 4-H), 5.31 (2H, s, CH<sub>2</sub>Ph), 5.29 (2H, s, CH<sub>2</sub>Ph), 5.22 (2H, s, CH<sub>2</sub>Ph), 4.13 (2H, s, 2-CH<sub>2</sub>), 4.05 (2H, s, 3-CH<sub>2</sub>), 2.57 (3H, s, CH<sub>3</sub>), 2.55 (3H, s, CH<sub>3</sub>), 2.51 (3H, s, CH<sub>3</sub>), 2.37 (3H, s, CH<sub>3</sub>); m/z (%) 739 (2,  $M^+$ ), 696 (20), 648 (27), 631 (20), 588 (95). (Found:  $M^+$  739.2890.  $C_{44}H_{41}N_3O_8$  requires 739.2893)

EXAMPLE 5Ethyl 6-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate

A solution of methyl pyrrole-2-carboxylate (0.222 g, 1.7 mmol) and ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate (0.474 g, 1.7 mmol) in 1,2-dichloroethane (20 cm<sup>3</sup>) was heated under reflux and stirred with Montmorillonite clay for 7 h. The reaction was followed to completion by TLC. After the clay had been filtered off and washed well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. Chromatographic separation of an oil eluting with (5-40%) ethylacetate in hexane gave Ethyl 6-methoxycarbonyl-3,4-dimethylpyrrolo[2,3-f]indole-2-carboxylate (isomer I) as a yellow solid after crystallisation from dichloromethane-petroleum ether (0.030 g, 5.62%), m.p. 245-248°C;  $\delta$ H ([<sup>2</sup>H<sub>6</sub>]-DMSO) 11.16 (1H, s, 5-NH), 11.00 (1H, s, 1-NH), 7.45 (1H, s, 8-H), 7.20 (1H, s 7-H), 4.37 (2H, q, OCH<sub>2</sub>CH<sub>3</sub>), 3.91 (3H, s, OCH<sub>3</sub>), 2.95 (3H, s, 3-CH<sub>3</sub>), 2.88 (3H, s, 4-CH<sub>3</sub>), 1.37 (3H, t, OCH<sub>2</sub>CH<sub>3</sub>); saturation of the 1-NH at  $\delta$  11.00 enhanced the signal due to 8-H at  $\delta$  7.45 (3.9%), saturation of the 4-CH<sub>3</sub> of  $\delta$  2.88 enhanced the signal due to 5-NH at  $\delta$  11.16 (12.3%) and saturation of the 5-NH at 11.16 enhanced the signal due to 4-CH<sub>3</sub> at  $\delta$  2.88 (2%); m/z (%) 314 (81, M<sup>+</sup>), 282 (55), 268 (89), 236 (100), 208 (56), 179 (50), 153 (48), 118 (56), 90 (82) and 77 (72) (Found: M<sup>+</sup>314.1267. C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> requires 314.1266; Ethyl 6-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate (isomer II) as yellow crystals after crystallisation from dichloromethane-petroleum ether (0.0584 g, 10.94%), m.p. 242-245°C;  $\delta$ H ([<sup>2</sup>H<sub>6</sub>]-DMSO) 11.36 (1H, s, 7-NH), 10.92 (1H,

s, 1-NH), 7.33 (1H, s, 8-H), 7.24 (1H, s 5-H), 4.36 (2H, q,  $\text{OCH}_2\text{CH}_3$ ), 3.89 (3H, s,  $\text{OCH}_3$ ), 2.92 (3H, s, 3- $\text{CH}_3$ ), 2.87 (3H, s, 4- $\text{CH}_3$ ), 1.37 (3H, t,  $\text{OCH}_2\text{CH}_3$ ); m/z (%) 314 (60,  $\text{M}^+$ ), 282 (50), 268 (62), 236 (60), 208 (60), 179 (55), 165 (34), 152 (52), 134 (48), 127 (56) and 188 (100) (Found:  $\text{M}^+$  314.1267.  $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_4$  requires 314.1266); Further elution gave 2-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl-5-methoxycarbonylpyrrole as off white crystals after crystallisation from dichloromethane-petroleum ether (0.0912 g, 16.16%), m.p. 160-162°C;  $\delta\text{H}$  ( $\text{CDCl}_3$ ), 10.40 (1H, s, 1-NH), 9.78 (1H, s, 1'-NH), 6.79 (1H, dd J 4 and 2.5, 4-H), 6.09 (1H, dd J 4 and 2.5, 3-H), 4.30 (2H, q,  $\text{OCH}_2\text{CH}_3$ ); 4.22 (2H, s,  $\text{CH}_2$ ), 3.80 (3H, s,  $\text{OCH}_3$ ), 2.58 (3H, s,  $\text{CH}_3$ ), 2.50 (3H, s  $\text{COCH}_3$ ), 1.33 (3H, t,  $\text{OCH}_2\text{CH}_3$ ); m/z (%) 332 (66,  $\text{M}^+$ ), 300 (55), 271 (54), 254 (66), 227 (61), 211 (55), 183 (65), 155 (59), 128 (66), 106 (85), 94 (45), 78 (66), 51 (37), 43 (100); and 2,3-di(3-acetyl-5-ethoxycarbonyl-4-methylpyrrol-2'-ylmethyl-5-methoxycarbonylpyrrole as off white crystals after crystallisation from benzene-petroleum ether (0.1885 g, 41.15%), m.p. 203-206°C (Found: C, 62.24; H, 6.16; N, 7.66.  $\text{C}_{28}\text{H}_{33}\text{N}_3\text{O}_8$  requires C, 62.32; H, 6.16; N, 7.79%);  $\delta\text{H}$  ( $\text{CDCl}_3$ ) 11.08 (1H, s, NH), 9.42 (1H, s, NH), 9.13 (1H, s, NH), 6.63 (1H, d J 2, 4-H), 4.33 (2H, q,  $\text{OCH}_2\text{CH}_3$ ); 4.32 (2H, q,  $\text{OCH}_2\text{CH}_3$ ), 4.13 (2H, s, 2- $\text{CH}_2$ ), 4.11 (2H, s, 3- $\text{CH}_2$ ), 3.77 (3H, s,  $\text{OCH}_3$ ), 2.61 (3H, s,  $\text{CH}_3$ ), 2.59 (3H, s,  $\text{CH}_3$ ), 2.57 (6H, s, 2 x  $\text{CH}_3$ ), 1.37 (3H, t,  $\text{OCH}_2\text{CH}_3$ ), 1.36 (3H, t,  $\text{OCH}_2\text{CH}_3$ ).

EXAMPLE 6Ethyl 7-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate(a) Reaction of 1-methoxycarbonylpyrrole and ethyl 5-acetoxy-methyl-4-acetyl-3-methylpyrrole-2-carboxylate

A solution of 1-methoxycarbonylpyrrole (1.000 g, 8 mmol) and ethyl 5-acetoxymethyl-4-acetyl-3-methyl-2-carboxylate (2.136 g, 8 mmol) in 1,2-dichloroethane (80 cm<sup>3</sup>) was heated under reflux and stirred with Montmorillonite clay (8 g) for 18 h. After the clay had been filtered off and washed well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. This was submitted to column chromatography eluting with (20-0%) petroleum ether in dichloromethane and (0-25%) ethyl acetate in dichloromethane to give the starting 1-methoxycarbonylpyrrole (0.1448 g, 14.48%); 3-chloro-5-ethoxycarbonyl-2-(1'-methoxycarbonylpyrrol-2'-ylmethyl)-4-methylpyrrole as colourless crystals after crystallisation from benzene-petroleum ether (0.0143 g, 5.51%) m.p. 144-145°C (Found: C, 55.27; H, 5.45; N, 8.43. C<sub>15</sub>H<sub>17</sub>N<sub>2</sub>O<sub>4</sub>Cl requires C, 55.47; H, 5.28; N, 8.63%);  $\delta$ H (CDCl<sub>3</sub>) 9.23 (1H, br s, NH), 7.20 (1H, t, J 2.5, 4'-H), 6.12 (2H, d J 2.5, 3'- and 5'-H), 4.29 (2H, q, OCH<sub>2</sub>CH<sub>3</sub>), 4.21 (2H, s, CH<sub>2</sub>), 3.97 (3H, s, OCH<sub>3</sub>), 2.26 (3H, s, CH<sub>3</sub>), 1.34 (3H, t, OCH<sub>2</sub>CH<sub>3</sub>); m/z (%) 326 (10, M<sup>+</sup>-2), 324 (28, M<sup>+</sup>), 297 (7), 295 (22), 289 (88), 279 (23), 277 (37); 243 (86), 221 (24), 219 (66), 185 (45), 155 (75), 142 (21), 128 (32), 101 (30), 90 (30), 80 (75), 67 (70), 59 (100).

Ethyl5-methoxycarbonyl-3,4-dimethylpyrrolo[2,3-f]indole-2-carboxylate (isomer I) as colourless crystals after crystallisation from dichlormethane-petroleum ether (0.0263 g, 1.05%) m.p. 163-165°C (Found: C, 64.73; H, 5.79; N, 8.77.  $C_{17}H_{18}N_2O_4$  requires C, 64.95; H, 5.77; N, 8.91%);  $\delta H$  ( $[^2H_6]$ -DMSO) 11.33 (1H, s, NH), 7.64 (1H, d J 3.5, 6-H), 7.38 (1H, s, 8-H), 6.72 (1H, d J 3.5, 7-H), 4.35 (2H, q,  $OCH_2CH_3$ ), 3.95 (3H, s,  $OCH_3$ ), 2.86 (3H, s, 3- $CH_3$ ), 2.75 (3H, s, 4- $CH_3$ ) and 1.37 (3H, t,  $OCH_2CH_3$ ); m/z (%) 314 (57,  $M^+$ ), 268 (100), 240 (18), 209 (19), 195 (25), 181 (52), 154 (42), 127 (28), 77 (26) and 59 (82); and Ethyl7-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate (isomer II) as colourless solid (0.6027 g, 23.99%) m.p. 197-200°C (Found: C, 64.82; H, 5.55; N, 8.74.  $C_{17}H_{18}N_2O_4$  requires C, 64.92; H, 5.77; N, 8.91%)  $\delta H$  ( $[^2H_6]$ -DMSO) 11.37 (1H, s, NH), 8.03 (1H, s, 8-H), 7.58 (1H, d J 3.5, 6-H), 6.88 (1H, d J 3.5, 5-H), 4.35 (2H, q,  $OCH_2CH_3$ ), 3.99 (3H, s,  $OCH_3$ ), 2.86 (6H, s, 2 x  $CH_3$ ), 1.36 (3H, t,  $OCH_2CH_3$ ); m/z (%) 314 (53,  $M^+$ ), 268 (100), 240 (13), 209 (21), 195 (12), 181 (12), 154 (13) and 127 (16). Further elution gave 3-acetyl-5-ethoxycarbonyl-2-(1'-methoxycarbonylpyrrol-2'-ylmethyl)-4-methylpyrrole as colourless solid (0.1588 g, 5.98%) m.p. 172-175°C (Found: C, 61.38; H, 6.22; N, 8.40.  $C_{17}H_{20}N_2O_5$  requires C, 61.43; H, 6.07; N, 8.43%);  $\delta H$  ( $CDCl_3$ ) 9.53 (1H, br s, NH), 7.21 (1H, dd J 3.5 and 2, 5'-H), 6.26 (1H, m, 4'-H), 6.13 (1H, t J 3.5, 3-H), 4.56 (2H, s,  $CH_2$ ), 4.31 (2H, q,  $OCH_2CH_3$ ), 3.95 (3H, s,  $OCH_3$ ), 2.59 (3H, s, 4- $CH_3$ ), 2.47 (3H, s,  $COCH_3$ ), and 1.35 (3H, t,  $OCH_2CH_3$ ); m/z (%) 332 (28,  $M^+$ ), 289 (92), 243 (100), 227 (22), 185 (28), 155 (16), 130 (10), 77 (24), 59 (35), 43 (90); 6-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)-2-ethoxycarbonyl-7-methoxycarbonyl-3,4-dimethylbenzo[1,2-b:5,4-b']dipyrrole as off white solid (0.1593 g, 7.64%)

m.p. 218-222°C (Found: C, 64.19; H, 5.89; N, 7.93.  $C_{28}H_{31}N_3O_7$  requires C, 64.48; H, 5.99; N, 8.06%);  $\delta H$  ( $[^2H_6]$ -DMSO) 12.08 (1H, s, pyr-NH), 11.32 (1H, s, 1-NH), 8.01 (1H, s, 8-H), 5.87 (1H, s, 5-H), 4.59 (2H, s,  $CH_2$ ), 4.34 (2H, q,  $OCH_2CH_3$ ), 4.28 (2H, q, pyr- $CO_2CH_2CH_3$ ), 4.05 (3H, s,  $OCH_3$ ), 2.79 (3H, s,  $CH_3$ ), 2.64 (3H, s,  $CH_3$ ), 2.59 (3H, s,  $CH_3$ ), 2.34 (3H, s,  $CH_3$ ), 1.36 (3H, t,  $OCH_2CH_3$ ), 1.33 (3H, t, pyr- $OCH_2CH_3$ ); m/z (%) 521 (2,  $M^+$ ), 478 (3), 432 (2), 386 (2), 370 (2), 355 (3), 342 (2), 300 (2), 193 (2), 179 (2), 105 (2), 91 (3) and 59 (100); and 2,5-di (3'-acetyl-5-ethoxycarbonyl-4-methylpyrrol-2'-ylmethyl)-1-methoxycarbonylpyrrole as colourless crystals after recrystallisation from dichloromethane-petroleum ether (0.1292 g, 5.99%) m.p. 227-230°C (Found: C, 62.27; H, 6.03; N, 7.60.  $C_{28}H_{33}N_3O_8$  requires C, 62.32; H, 6.16; N, 7.79%);  $\delta H$  ( $[^2H_6]$ -DMSO) 11.95 (2H, s, 2 x NH), 5.19 (2H, s, 3- and 4-H), 4.38 (4H, s, 2 x  $CH_2$ ), 4.24 (4H, q, 2 x  $OCH_2CH_3$ ), 4.01 (3H, s,  $OCH_3$ ), 2.50 (6H, concealed by DMSO, 2 x  $COCH_3$ ), 2.28 (6H, s, 2 x  $CH_3$ ), 1.29 (6H, t, 2 x  $OCH_2CH_3$ ); m/z (%) 539 (34,  $M^+$ ), 521 (34), 507 (8), 494 (13), 464 (15), 418 (13), 370 (14), 331 (99), 285 (85), 273 (40), 227 (58), 207 (46), 162 (87) and 59 (100).

(b) Cyclisation of 3-acetyl-5-ethoxycarbonyl-2-(1'-methoxy-carbonylpyrrole-2'-ylmethyl)-4-methylpyrrole

Toluene-p-sulfonic acid (100 mg) was added to the solution of the 3-acetyl-5-ethoxycarbonyl-2-(1'-methoxy-carbonylpyrrol-2'-ylmethyl)-4-methylpyrrole (0.435 g, 1.31 mmol) in benzene (50 cm<sup>3</sup>), the reaction mixture was heated under reflux for 5h (using Dean-Stark apparatus). On cooling, the product crystallised, the crystals were filtered and washed with ethanol giving Ethyl 7-methoxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-

carboxylate (isomer II) as colourless crystals (0.3264 g, 79.34%) m.p. 197-200°C which was identical to the benzo[1,2-b:5,4-b']dipyrrole (isomer II) from the previous experiment by TLC and NMR. Chromatographic separation of the remaining filtrate eluting with (5-0%) petroleum ether in dichloromethane and (0-10%) ethyl acetate in dichloromethane yielded Ethyl 5-methoxycarbonyl-3,4-dimethylpyrrolo[2,3-f]indole-2-carboxylate (isomer I) as colourless solid (0.002g, 0.49%) which was identical to the pyrrolo[2,3-f] indole (isomer I) from the previous experiment. Also obtained were the pyrrolo[3,2-f]indole (isomer II) (0.0313 g, 7.61%) and the starting 2-pyrrolylmethylpyrrole (0.0125 g, 2.87%).

#### EXAMPLE 7

##### **Ethyl 3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate**

5% Potassium hydroxide (10 cm<sup>3</sup>) was added to a solution of ethyl 7-methoxy-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate (example 6 isomer II) (0.314 g, 1.0 mmol) in tetrahydrofuran (100 cm<sup>3</sup>) and the reaction mixture was heated at gentle reflux and stirred for 48 h. After cooling, the reaction mixture was diluted with water (3 x 50 cm<sup>3</sup>). The combined extracts were washed with water and then evaporated under reduced pressure to give a yellow solid. This was submitted to column chromatography eluting with (10-25%) ethylacetate and 10% dichloromethane in petroleum ether to give the starting pyrroloindole (0.031 g, 9.87%) and ethyl 3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate as a pale green solid (0.169 g, 66.02%) m.p. 233-235°C;  $\delta$ H (CDCl<sub>3</sub>) 8.36 (1H, br s, 1-NH), 7.86 (1H, br s, 7-NH), 7.17 (1H, dd J 3.3 and

2.4, 6-H), 7.09 (1H, s, 8-H), 6.62 (1H, m, 5-H), 4.14 (2H, q,  $\text{OCH}_2\text{CH}_3$ ), 2.96 (3H, s, 3- $\text{CH}_3$ ), 2.94 (3H, s, 4- $\text{CH}_3$ ) and 1.43 (3H, t,  $\text{OCH}_2\text{CH}_3$ );  $m/z$  (%) 256 (28,  $M^+$ ), 227 (5), 210 (100), 181 (99), 168 (28), 154 (89), 140 (15), 126 (63), 77 (42), 63 (32).

#### ASSAYS FOR COMPOUND ACTIVITY

Assays for cell proliferation/cytotoxicity were carried out in tissue culture grade 96 well microtitre plates (Costar). Cells in log growth were added to the plates at a concentration of  $1 \times 10^3$  cells per well on day 0 and serially diluted compounds were then added on day 1. Plates were then incubated at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  in air for a further 4 days.

For quantitation of cell growth, the methylene blue biomass staining method was used, the test being read on a Multiscan plate reader at wavelength of 620nm. The morphology of the cells was checked microscopically under phase-contrast immediately before the fixation and staining with methylene blue, and by ordinary light microscopy thereafter.  $\text{IC}_{50}$  values for active compounds were obtained using the computer programme, GS1 and dose-response slopes were also plotted.


When compounds were tested for activity in a colony forming assay the methods used were identical to those described earlier except that serially diluted compound was added to the sloppy agar when the test was set up, and replenished at the same concentration on day 7. The test results were read on day 14.

RESULTS:


<u>Example Compound</u>	<u>IC50(<math>\mu</math>M) (HT1080scc2)</u>
1	100
2	3

CLAIMS

1. A compound of the formula (I):



or a salt or physiologically functional derivative thereof,  
wherein A is



X is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>, wherein R<sup>7</sup> is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl, sulphonyl, substituted sulphonyl, or COOMe;

Y is O, S, SO, SO<sub>2</sub>, CH<sub>2</sub>, CO or NR<sup>7</sup>;

R<sup>1</sup> is COR<sup>8</sup>, CHO, CH<sub>2</sub>OH, CH<sub>2</sub>OR<sup>9</sup>, CONH<sub>2</sub>, COOR<sup>8</sup>, CONHR<sup>8</sup>, CONR<sup>8</sup>R<sup>9</sup>, CSOR<sup>8</sup>, CSSR<sup>8</sup>, COSR<sup>8</sup>, CSNHR<sup>8</sup>, CSNR<sup>8</sup>R<sup>9</sup>, CNHOR<sup>8</sup> wherein R<sup>8</sup> and R<sup>9</sup> are independently hydrogen, alkoxyalkyl, heterocycloalkyl, heteroaralkyl, or C<sub>1-10</sub> optionally

substituted hydrocarbonyl group which may optionally contain one or two oxygen atoms in the chain;

or  $R^8$  and  $R^9$  are a sugar group.


$R^2$  is H, halo, cyano,  $COOR^8$ , alkyl, aryl, alkenyl, alkynyl, alkoxy, (wherein alkyl, aryl, alkenyl, alkynyl and alkoxy can be substituted) or  $CH_2CH_2CO_2R^{12}$  wherein  $R^{12}$  is alkyl or aryl;

$R^3$  is H, alkyl, halogen, cyano, amino,  $COOR^8$ ,  $CONHR^8$ ,  $COR^8$ ,  $CH_2OH$ ,  $CH_2OR^8$ ,  $CONH_2$ ,  $CONR^8R^9$ ,  $CSOR^8$ ,  $CSSR^8$ ,  $COSR^8$ ,  $CSNHR^8$ ,  $CSNR^8R^9$  or  $CNHOR^8$ ;


$R^4$  is H, halogen, cyano, amino, alkyl,  $COOR^8$ ,  $CONHR^8$ ,  $COR^8$ ,  $CH_2OH$ ,  $CH_2OR^8$ ,  $CONH_2$ ,  $CONR^8R^9$ ,  $CSOR^8$ ,  $CSSR^8$ ,  $COSR^8$ ,  $CSNHR^8$ ,  $CSNR^8R^9$  or  $CNHOR^8$ ;

$R^5$  is H, hydroxy, aryloxy, aralkyloxy, alkyl, substituted alkyl, aralkyl, nitro, amino, halo, cyano  $COOR^8$  or  $CHO$ ;

$R^6$  is H, aryl, alkyl, aralkyl, nitro, halogen,  $CHO$  or  $COR^{13}$  wherein  $R^{13}$  is alkyl or aryl; wherein  $R^8$  is not H when  $R^2$  is H and  $R^3$  is not H or Me when A is



2. A compound as claimed in claim 1, wherein A is:



Y is NH or NCOOMe;

R<sup>1</sup> is COOR<sup>a</sup>, wherein R<sup>a</sup> is alkyl or aralkyl;

R<sup>2</sup> is H, alkyl or COOR<sup>a</sup>, wherein R<sup>a</sup> is alkyl;

R<sup>3</sup> is H, alkyl or COOR<sup>a</sup>, wherein R<sup>a</sup> is alkyl;

R<sup>4</sup> is alkyl or COOR<sup>a</sup>;

R<sup>5</sup> is H; and

R<sup>6</sup> is H or methyl;

and salts and physiologically functional derivatives thereof.

3. A compound as claimed in claim 1 or claim 2 which is:

Ethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2-carboxylate;

Diethyl 1,7-dihydro-3,4,6-trimethylpyrrolo[3,2-f]indole-2,5-dicarboxylate; and

Ethyl 6-methoxycarbonyl-3,4-dimethyl pyrrolo[3,2-f]indole-2-carboxylate

and physiologically functional derivatives thereof.

4. A compound as claimed in claim 1 or claim 2 which is:

Ethyl 6-Benzylloxycarbonyl-3,4-dimethylpyrrolo[3,2-f]indole-2-carboxylate;


Dibenzyl 3,4-dimethylpyrrolo[3,2-f]indole-2,6-dicarboxylate;

Ethyl 7-methoxycarbonyl-3,4-dimethyl  
 pyrrolo[3,2-f]indole-2-carboxylate; and  
 Ethyl 3,4-dimethylpyrrolo[3,2-f]indole-2-  
 carboxylate


and physiologically functional derivatives thereof.

5. A process for the preparation of a compound of formula (I) which comprises the step of:

(a) reacting a compound of formula (II) with a compound of formula (III):



(II)



(III)

wherein X, Y, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in claim 1, except that R<sup>3</sup> and R<sup>4</sup> are not hydrogen when X is NH, in an inert solvent;

(b) carboxylation of a polyheterocyclic compound using:

- (i) a carbonyl halide; or
- (ii) carbon dioxide;

(c) reacting a polyheterocyclic compound with a formylating agent;

(d) reacting a polyheterocyclic compound carrying a functional group selected from  $\text{CHBr}_2$ ,  $\text{CH}_3$  or  $\text{COR}^{14}$ , wherein  $\text{R}^{14}$  is a primary or secondary  $\text{C}_{1-6}$  alkyl group,  $\text{COOH}$  or a derivative thereof, to convert the functional group to an aldehyde; or

(e) converting one compound of formula (I) into another compound of formula (I).

6. The use of a compound as claimed in any one of claims 1 to 4 in medicine.

7. The use as claimed in claim 6 for treating cancer.

8. A pharmaceutical formulation comprising at least one compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or physiologically functional derivative thereof, together with one or more pharmaceutically acceptable diluents, carriers or excipients.

9. The use of a compound of formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of cancer.

## INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/GB 95/00203

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D487/04 A61K31/40 //(C07D487/04,209:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IL FARMACO - ED. SC., vol. 34, no. 9, 1979 pages 774-783, GUIOTTO ET AL. 'Bis-basic derivatives of planar heterocyclic compounds' see whole document ---	1
X	PHARM. CHEM. J., vol. 18, no. 12, 1984 pages 819-823, SAMSONIYA; LOMTATIDZE; DOLIDZE; SUVOROV 'Synthesis and biocidal properties of some 1H,6H-pyrrolo[2,3-e]indole and 1H,7H-pyrrolo[3,2f]indole derivatives' see compounds X-XII --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 May 1995

Date of mailing of the international search report

- 8. 06. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Lauro, P

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/00203

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARZNEIM. FORSCH./DRUG RES., vol. 29,no. 8, 1979 pages 1081-1083, HISHMAT; EL-EBRASHI; SHALASH; ISMAIL 'Synthesis of Difuran Derivatives and their Biological Activity' see compounds of formula III ---	1
X	EUR. J. MED. CHEM - CHIM. THER., vol. 12,no. 1, 1977 pages 31-34, RENE ET AL. 'Analogues difurobenzéniques et furochroméniques du psoralène et du pseudopsoralène' see compounds of formula 12,13,14 ---	1
X	TETRAHEDRON, vol. 29, 1973 pages 921-927, KUCKLAENDER 'Beobachtungen zum Mechanismus der Nenitzescu-Reaktion' see compounds of formula 9,10,11,15 ---	1
X	CHEM. HETEROCYCL. COMPD., vol. 13, 1977 pages 621-624, GRINEV ET AL. 'Synthesis of furio[2,3-f]- and furo[3,2-e]indole derivatives' see compounds of formula I,V,VI ---	1
X	CHEM. HETEROCYCL. COMPD., vol. 19, 1983 pages 871-876, KADZHRISHVILI ET AL. 'Electrophilic substitution in the 1H,5H-pyrrolo[2,3-f]indole and 3H,6H-pyrrolo[3,2-e]indole series' see compounds of formula II, III ---	1
X	ACTA CHEM. SCAND., vol. 15,no. 2, 1961 pages 429-430, BERNATEK 'Bromination and subsequent Ozonisation of Ethyl 2,6-Dimethylbenzo[1.2-b,4.5-b']difuran-3,7 -dicarboxylate' see page 429, column 1 ---	1
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/00203

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 93, no. 21, 24 November 1980 Columbus, Ohio, US; abstract no. 204496w, page 675; see abstract & ACTA POL. PHARM., vol. 36, no. 6, 1979 pages 651-655, & RN = 75449-52-4      RN = 75449-51-3 RN = 75449-47-7 ---	1
X	CHEMICAL ABSTRACTS, vol. 102, no. 1, 7 January 1985 Columbus, Ohio, US; abstract no. 6243c, page 567; see abstract & KHIM. GETEROTSIKL. SOEDIN, vol. 9, 1984 page 1219-1222 ---	1
X	CHEMICAL ABSTRACTS, vol. 114, no. 19, 13 May 1991 Columbus, Ohio, US; abstract no. 185077u, page 747; see abstract & BULL. SOC. CHIM. BELG., vol. 100, no. 1, 1991 page 1-4 ---	1
X	DE, A, 19 02 050 (FARBENFABRIKEN BAYER) 13 August 1970 see page 3; example 2; table I ---	1
A	US, A, 5 248 692 (KYOWA HAKKO KOGYO) 28 September 1993 see page 1, column 1 -----	1

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/00203

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-1902050	13-08-70	BE-A- 744509 CH-A- 523904 FR-A- 2028476 GB-A- 1259563 NL-A- 7000441 US-A- 3663568	16-07-70 15-06-72 09-10-70 05-01-72 20-07-70 16-05-72
US-A-5248692	28-09-93	EP-A- 0461603 JP-A- 4226988 US-A- 5214065	18-12-91 17-08-92 25-05-93